To the news listNew! Immunohistochemical Screening for Cervical Cancer (p16INK4a + Ki-67)
OLIMP CDL is expanding the possibilities of morphological diagnostics and introduces a new test - immunohistochemical screening for cervical cancer with the assessment of p16INK4a and Ki-67 markers.
This study is used to detect and further characterize HPV-associated precancerous changes of the cervical epithelium. The combined evaluation of p16INK4a and Ki-67 expression improves the diagnostic accuracy of cervical intraepithelial neoplasia (CIN) and helps physicians determine the most appropriate patient management strategy.
When is this test recommended ?
- When cervical dysplasia is suspected;
- When high-risk oncogenic HPV has been detected;
- In cases of inconclusive histological findings;
- To confirm high-grade cervical intraepithelial neoplasia;
- When there is a discrepancy between clinical, colposcopic, and morphological findings.
Diagnostic significance of the test
- p16INK4a - is a marker of HPV-associated transformation of cervical epithelial cells.
- Ki-67 - reflects the proliferative activity of cells and allows assessment of the intensity of the pathological process. The combined evaluation of these markers contributes to a more accurate diagnosis of precancerous lesions and helps differentiate reactive changes from true neoplastic processes.
Biomaterial
Cervical biopsy material prepared in the form of a paraffin block.
Advantages of the test
- Improved accuracy in diagnosing precancerous cervical lesions;
- Additional information for pathologists and clinicians;
- Assistance in selecting further monitoring and treatment strategies;
- High diagnostic value in HPV-associated lesions.
Modern immunohistochemical methods enable the detection of clinically significant changes at early stages and provide more accurate morphological diagnosis of cervical diseases.
